Company Overview and News

 
Kelvin Ryan heads east

2018-02-08 businessnews.com.au
Former BGC Residential chief executive Kelvin Ryan has been appointed as managing director at Melbourne-based building company Simonds Group.
Upvote Downvote

 
ASX rallies into Christmas break on miners, banks

2017-12-22 theage.com.au
The ASX ended the last session before the Christmas break on an upbeat note, with traders choosing to pick up  miners and banks ahead of the holiday.
Upvote Downvote

 
ASX rallies into Christmas break on miners, banks

2017-12-22 smh.com.au
The ASX ended the last session before the Christmas break on an upbeat note, with traders choosing to pick up  miners and banks ahead of the holiday.
Upvote Downvote

 
Simonds Group to shuffle the deck

2017-09-20 proactiveinvestors.com.au
Simonds Group Ltd (ASX:SIO) has been granted a trading halt by the ASX, pending details in relation to its board structure.
Upvote Downvote

 
The IPOs that have investors thinking twice about buying new shares

2016-12-16 theage.com.au
On a balmy November evening in Fremantle, a steer being loaded onto a cattle ship bound for offshore meat markets made a mad dash for freedom, jumping into the water and swimming ashore.
Upvote Downvote

 
The IPOs that have investors thinking twice about buying new shares

2016-12-16 smh.com.au
On a balmy November evening in Fremantle, a steer being loaded onto a cattle ship bound for offshore meat markets made a mad dash for freedom, jumping into the water and swimming ashore.
Upvote Downvote

 
Simonds Group Ltd granted an ASX trading halt

2016-09-21 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Upvote Downvote

 
Simonds Group Ltd looks to change control

2016-08-30 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...